Last updated: 2026-09-10 08:02:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
MediWound Ltd. (MDWD) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $13,83, with a market capitalization of $173,51M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $12,52 to $20,30. This page covers its latest market performance, valuation, price trends and company information.
$173,51M | |
$13,41 | |
$135,17 | |
$7,10 | |
$13,44 | |
205,49K | |
86,79K | |
-- | |
$20,30 | |
$12,52 | |
-- | |
-- |
MediWound Ltd. (MDWD) is trading at $13,42 in pre-market trading as of 2026-09-09 23:31:00, down 0,19% ($0,03) from the previous close of $13,44
Pre-market trading shows how investors are pricing MDWD before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, MediWound Ltd. (MDWD) moved from $12,61 to $13,83, representing a gain of 9,64% ($1,21).
The stock traded between $12,55 and $14,07 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 138,30 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 16,8%
MDWD is currently trading at $13,83, placing it 16,8% of the way from its 52-week low of $12,52 to its 52-week high of $20,30. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
| Employees | 121 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of MediWound Ltd. (MDWD) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.